Erratum: Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling (International journal of oncology (2018) 53 3 (1069-1082))
单位:[1]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China华中科技大学同济医学院附属同济医院外科学系神经外科
Following the publication of this article, the authors have realized that the name of the second author was misspelt: "Minghai Dong" should have appeared as "Minhai Dong". The correct information for the authors on this paper is presented above. The authors regret that this error made it into print, andapologize to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 53: 1069‑1082, 2018; DOI: 10.3892/ijo.2018.4482].
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版:
大类|3 区医学
小类|3 区肿瘤学
第一作者:
第一作者单位:[1]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
推荐引用方式(GB/T 7714):
Xiao Q,Dong M,Cheng F,et al.Erratum: Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling (International journal of oncology (2018) 53 3 (1069-1082))[J].International journal of oncology.2019,54(6):2257.doi:10.3892/ijo.2019.4769.
APA:
Xiao, Q,Dong, M,Cheng, F,Mao, F,Zong, W...&Guo, D.(2019).Erratum: Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling (International journal of oncology (2018) 53 3 (1069-1082)).International journal of oncology,54,(6)
MLA:
Xiao, Q,et al."Erratum: Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling (International journal of oncology (2018) 53 3 (1069-1082))".International journal of oncology 54..6(2019):2257